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Abstract 
Background: The interferon-inducible factor BST-2/tetherin blocks the release of nascent virions from the surface 
of infected cells for certain enveloped virus families. The primate lentiviruses have evolved several counteracting 
mechanisms which, in the case of HIV-2, is a function of its Env protein. We sought to further understand the features 
of the Env protein and tetherin that are important for this interaction, and to evaluate the selective pressure on HIV-2 
to maintain such an activity.
Results: By examining Env mutants with changes in the ectodomain of the protein (virus ROD14) or the cytoplasmic 
tail (substitution Y707A) that render the proteins unable to counteract tetherin, we determined that an interaction 
between Env and tetherin is important for this activity. Furthermore, this Env-tetherin interaction required an alanine 
face in the tetherin ectodomain, although insertion of this domain into an artificial tetherin-like protein was not suf-
ficient to confer sensitivity to the HIV-2 Env. The replication of virus carrying the ROD14 substitutions was significantly 
slower than the matched wild-type virus, but it acquired second-site mutations during passaging in the cytoplasmic 
tail of Env which restored the ability of the protein to both bind to and counteract tetherin.
Conclusions: These results shed light on the interaction between HIV-2 and tetherin, suggesting a physical interac-
tion that maps to the ectodomains of both proteins and indicating a strong selection pressure to maintain an anti-
tetherin activity in the HIV-2 Env.
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  pcannon@usc.edu 
Department of Molecular Microbiology and Immunology, Keck School 
of Medicine, University of Southern California, 2011 Zonal Avenue, HMR 
502, Los Angeles, CA 90033, USA
Background
Tetherin/BST-2 is a multi-functional cellular protein 
that plays roles in cell membrane organization, as well 
as contributing to both the sensing and inhibition of 
enveloped virus replication [reviewed in 1]. Depending 
on the cell type, tetherin can be constitutively expressed 
or stimulated by interferon [2–5]. Tetherin localizes to 
lipid raft membrane microdomains, where it links to the 
actin cytoskeleton and helps to stabilize the apical actin 
network and microvilli in polarized cells [6, 7]. Tetherin 
also has antiviral properties, that were first described 
against HIV-1 [8, 9]. In HIV-1 infected cells, tetherin 
retains newly assembled virions at the cell surface which 
both reduces the production of cell-free virus [8, 10] 
and also promotes natural killer cell mediated antibody-
dependent killing of infected cells [11–13]. Additionally, 
the human form of tetherin, and to a lesser extent chim-
panzee tetherin, can act as pattern recognition receptors, 
since cross-linking of the protein by tethered virions or 
antibodies activates the NF-κB pathway and promotes 
entry into an antiviral state [14, 15].
Structurally, tetherin is a type 2 transmembrane gly-
coprotein, with a short cytoplasmic tail and membrane-
spanning domain at its N-terminus, and a GPI anchor 
at its C-terminus [6]. These membrane anchors flank 
an extracellular coiled-coil domain that mediates teth-
erin–tetherin interactions and promotes the formation 
of parallel homodimers, which can be further organized 
into tetramers [16, 17]. Tetherin retains budding viri-
ons at the cell surface in an axial conformation, with the 
GPI anchors preferentially incorporated into virions and 
the transmembrane domains anchored in cellular mem-
branes [18]. All three of the major structural features 
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of the protein are required for its ability to inhibit virus 
release [8, 19, 20], although the actual sequences are not 
essential, and its function can be recapitulated in a wholly 
artificial tetherin construct [20].
Since tetherin presents a barrier to virus replication at 
multiple levels, it is not surprising that the primate len-
tiviruses have evolved several strategies to counteract its 
actions. Most SIVs use the Nef protein to block tetherin 
[21–25], in a mechanism based on intracellular seques-
tration via a direct physical interaction between Nef and 
tetherin’s cytoplasmic tail [26]. Alternatively, some SIVs 
such as SIVgsn use Vpu to counteract tetherin, and Vpu 
persists as the viral anti-tetherin factor in present day 
group M HIV-1 [8, 9, 23]. Here the mechanism is also 
predominantly through intracellular sequestration, com-
bined with ubiquitination and endolysosomal degrada-
tion [27–32]. A direct physical interaction between Vpu 
and tetherin has also been reported, that maps to the 
trans-membrane domains of each protein [33, 34].
In HIV-2, which does not encode Vpu, the anti-teth-
erin factor is the Env protein [35–37]. HIV-2 Env has 
been reported to both interact with tetherin [37] and to 
remove it from the cell surface, leading to its concen-
tration in a perinuclear compartment [29, 37, 38]. This 
interaction appears to be mediated by the extracellular 
domains of the two proteins since a chimeric Env com-
prising the extracellular domain of HIV-2 Env linked to 
the transmembrane and cytoplasmic domains of the non-
functional HIV-1 Env is still able to antagonize tetherin 
[35]. Conversely HIV-2 Env can counteract a tetherin 
derivative substituted with the transmembrane and cyto-
plasmic domains of the transferrin receptor, but retain-
ing the extracellular domain and GPI anchor of native 
tetherin [38]. In addition to a requirement for the extra-
cellular domain of HIV-2 Env, a tyrosine based sorting 
motif in the cytoplasmic tail has also been shown to be 
required for anti-tetherin activity [37, 39].
In the present study, we sought to more fully map the 
determinants in tetherin and the HIV-2 Env that allow 
their interaction, and to investigate the impact of the loss 
of anti-tetherin activity on HIV-2 replication. Specifically, 
we asked whether there was a selective pressure for a 
virus that had lost the ability to antagonize tetherin fol-
lowing mutation of Env to re-acquire this function, and 
whether this would once again map to the Env protein.
Results
Interaction of HIV‑2 Env and tetherin is required 
for tetherin antagonism
Previously, it was reported that the Env protein from 
HIV-2 strain ROD10 can be co-immunoprecipitated with 
tetherin [37]. However it was not established if this inter-
action was necessary for the Env protein’s anti-tetherin 
activity. To analyze this further, we selected two closely 
related mutants of ROD10 Env that do not counteract 
tetherin [29, 37], and evaluated their ability to bind to 
the protein. The ROD14 Env differs from ROD10 Env at 
5 specific amino acids, and contains a 30 amino acid dele-
tion in its cytoplasmic tail [40], with substitutions K422R 
and A598T in the ectodomain of the protein being pri-
marily responsible for its loss of tetherin antagonism 
[41]. In addition, mutant ROD10 EnvY707A contains a 
point mutation that disrupts an endocytosis motif in its 
cytoplasmic tail, and this is sufficient to prevent tetherin 
antagonism [35, 37]. We confirmed that both of these 
Env variants lacked the ability to counteract tetherin, 
since they could not stimulate the release of HIV-1 Gag-
Pol virus-like particles (VLPs) from tetherin-expressing 
cells (Fig. 1a).
To examine whether the two mutants Envs were still 
capable of binding to tetherin, we created GFP-tagged 
versions of all three Env proteins to facilitate co-immu-
noprecipitation assays using anti-GFP antibodies. As 
expected, no tetherin was immunoprecipitated when it 
was co-expressed with GFP alone, or when an untagged 
ROD10 Env was used. However co-expression of tetherin 
with a GFP-tagged ROD10 Env allowed its pull-down 
(Fig.  1b). In contrast, the ROD14 Env mutant did not 
interact with tetherin. Interestingly, despite its complete 
lack of tetherin antagonism, the ROD10 EnvY707A mutant 
was still able to immunoprecipitate some tetherin, and 
when the lower cellular levels of the ROD10 EnvY707A 
protein were taken into consideration, it was found to be 
67% (n = 3 experiments) as efficient at immunoprecipi-
tating tetherin as the WT ROD10 Env (data not shown). 
These differences may be sufficient to account for its lack 
of anti-tetherin activity or, alternatively, this may result 
from some other characteristic of the Y707A mutant, 
such as being present in a different cellular localization 
than the WT Env, or because the loss of its endocytosis 
signal makes it unable to remove tetherin from the cell 
surface, as we and others have previously reported [29, 
37].
The extracellular domain of HIV‑2 Env is not sufficient 
for anti‑tetherin activity
Since the interaction between tetherin and Env has 
been suggested to map to the extracellular domains 
of both proteins [35, 38], we sought to determine if the 
extracellular domain of the HIV-2 Env alone was suf-
ficient for tetherin counteraction. To test this, we cre-
ated a GPI anchored version of a truncated ROD10 Env 
protein (Envgpi), allowing the extracellular domain to 
be expressed on the cell surface in the absence of the 
membrane spanning domain and cytoplasmic tail. We 
found that expression of the ROD10 Envgpi was unable 
Page 3 of 13Exline et al. Retrovirology  (2015) 12:67 
to overcome tetherin restriction (Fig.  2a) despite the 
construct having robust cell surface expression (Fig. 2b) 
and being able to co-immunoprecipitate with tetherin 
(Fig. 2c). Together, these results indicate that while deter-
minants sufficient to promote an Env-tetherin interaction 
are present in the ectodomain of Env, the membrane-
spanning and/or intracellular domains of the protein are 
also required for functional tetherin antagonism. Such a 
requirement could reflect an interaction of this domain 
with an additional cellular partner, or the need for signals 
enabling co-localization of Env with tetherin at the cell 
surface, and/or endocytosis.
An alanine motif in tetherin’s coiled‑coil domain controls 
sensitivity to HIV‑2 Env
We have previously shown that an alanine to aspartic 
acid substitution at position 100 of tetherin (A100D) 
makes the protein resistant to the HIV-2 Env [38] and a 
similarly located mutation in Tantalus monkey tetherin 
renders that protein resistant to SIVTan Env [42]. We 
next addressed whether the change to an acidic residue 
was important, or was it simply the loss of the specific 
alanine residue. Substitution of either a basic residue 
(arginine) or another uncharged residue (glycine) also 
rendered tetherin insensitive to HIV-2 Env, suggesting a 
specific role for the alanine residue. In contrast each teth-
erin mutant retained sensitivity to the HIV-1 Vpu protein 
(Fig. 3a).
We next asked whether the HIV-2-resistant phenotype 
of tetherin A100D was a result of disrupting the inter-
action between the two proteins. As described earlier, a 
GFP-tagged ROD10 Env can specifically immunoprecipi-
tate the wild-type tetherin. However, the A100D mutant 
was not immunoprecipitated by the HIV-2 Env (Fig. 3b), 
suggesting that this substitution directly impacted the 
interaction between the two proteins, and accounts for 
the insensitivity of the mutant tetherin to HIV-2 Env.
Investigation of the sequence surrounding the A100 
residue in tetherin revealed the presence of additional 
alanines at positions 97, 100, 104, and 107 (Fig.  3c), 
which are also highly conserved among primate tether-
ins, but absent in porcine tetherin. When mapped onto 
the crystal structure of a dimer of tetherin’s coiled-coil 
domain [17], these alanines were seen to line up on a sin-
gle face, opposite to the dimerization interface, suggest-
ing that they could be accessible to other protein partners 
such as HIV-2 Env. To test the hypothesis that the ala-
nine face contributed to the interaction with HIV-2 Env, 
Fig. 1 HIV-2 Env mutants that disrupt the interaction with tetherin. a HIV-1 Gag-Pol VLPs were created by transfecting 293A cells with pHIV-1-pack, 
together with a control CMV expression plasmid (−) or expression plasmids for tetherin and the indicated Envs. 24 h later, VLP release was measured 
as the ratio of p24-reacting bands in supernatants versus cell lysates following Western blot analysis. Results were normalized to the no tetherin 
control which was set at 100% VLP release. Graphs show mean plus standard deviation for n = 3 independent experiments, p < 0.05 (*). b 293T cells 
were co-transfected with tetherin and GFP-tagged Env variants. Cells were lysed 24 h later and GFP-tagged proteins were immunoprecipitated (IP) 
with anti-GFP MicroBeads, followed by Western blotting of the input lysates (1%) and IP products using anti-Env, anti-GFP or anti-tetherin antibod-
ies.
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we introduced single aspartic acid substitutions at each 
of the four positions and tested the resulting tetherin 
mutants for their ability to inhibit HIV-1 VLP release, 
and to be counteracted by the ROD10 Env (Fig. 3d). We 
found that while each mutant tetherin retained the abil-
ity to restrict VLP release, and remained sensitive to Vpu, 
substitution of any of the alanines rendered the mutant 
tetherins completely resistant to ROD10 Env. These 
results therefore identify an alanine face on tetherin as 
being necessary for both the interaction with HIV-2 Env 
and the resulting ability of the protein to counter tetherin 
restriction.
The conserved alanine motif does not render an artificial 
tetherin‑like molecule sensitive to HIV‑2 Env
Artificial tetherin (art-tetherin) contains the same struc-
tural features as native tetherin, but without the conser-
vation of any primary sequence [20]. It is able to restrict 
HIV-1 release, but is resistant to both Vpu and HIV-2 
Env, suggesting a sequence specific interaction between 
tetherin and these antagonists. However, it can be over-
come by co-expression of the Ebola GP, which appears to 
use a different mechanism of action against tetherin [38, 
43].
In order to examine whether the conserved alanine 
motif in the ectodomain of tetherin was sufficient to 
confer an interaction with HIV-2 Env, we inserted a 13 
amino acid stretch of tetherin containing these alanines 
into the extracellular domain of art-tetherin (Fig. 4a). The 
sequence was inserted at four positions, each one amino 
acid apart, in an effort to promote exposure of the ala-
nine face on the outside of the coiled-coil motif in at least 
one variant. Only two of the constructs, with inserts at 
positions 114 and 116, retained restrictive activity (data 
not shown), and these were further tested for sensitivity 
to both Ebola GP and ROD10 Env. As expected, both art-
tetherin and the two insertional mutants remained sensi-
tive to the Ebola GP (Fig. 4b). However, the addition of 
the alanine motif did not result in the acquisition of sen-
sitivity to the HIV-2 Env, suggesting that the presence of 
the alanine face alone may not be sufficient to promote 
a functional interaction with HIV-2 Env. Furthermore, 
none of the art-tetherin constructs co-immunoprecipi-
tated with ROD10 Env (Fig. 4c).
Rates of HIV‑2 replication in the presence of ROD10 
and ROD14 Envs
While it is well established that the presence of the 
HIV-2 Env can enhance virus release in one-round 
assays, its impact on a spreading virus replication 
is less well characterized, although initial studies 
indicated that the ROD14 virus replicated less effi-
ciently than the ROD10 virus [40]. To investigate this 
further, and to ensure that any differences in viral 
Fig. 2 The HIV-2 Env ectodomain is not sufficient to overcome tetherin. a HIV-1 VLPs were produced in the presence of the WT ROD10 Env, or 
increasing amounts of ROD10 Envgpi (2, 4, 8 μg). VLP release was analyzed by Western blotting and results normalized to the no tetherin control, 
for n = 3 independent experiments, p < 0.05 (*). b Cell surface expression of ROD10 Envgpi was confirmed by flow cytometry. The light grey line 
represents cells stained with secondary antibody only, the dark line represents the indicated ROD10 Env variant. Mean fluorescence intensity (MFI) 
for each panel is shown. c 293T cells were co-transfected with tetherin or GFP-tagged tetherin, together with ROD10 Env or ROD10 Envgpi at the 
indicated amounts. Cells were lysed 24 h later and GFP-tagged proteins were immunoprecipitated (IP) with anti-GFP MicroBeads, followed by West-
ern blotting of the input lysates (1%) and IP products using anti-Env or anti-tetherin antibodies.
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replication were due only to defined Env mutations, 
we inserted the ROD14 Env mutant into the backbone 
of the wild-type ROD10 proviral clone to create virus 
ROD10(14Env). Virus stocks were created by trans-
fecting these proviral clones into 293T cells, which 
do not express tetherin, allowing both wild-type and 
mutant viruses to be produced as virus stocks with 
similar titers. These stocks were then used to estab-
lish a spreading infection in JLTRG reporter cells, 
which express tetherin (data not shown), by assay-
ing the cells for GFP expression as a readout of virus 
replication. We found that the ROD10(WT Env) virus 
reached a peak of infection at day 13, with about 45% 
of the JLTRG cells expressing GFP. In contrast, the 
ROD10(14 Env) mutant virus exhibited delayed repli-
cation kinetics and only began to spread through the 
population at day 22 (Fig. 5a).
The late rise in virus replication seen for the mutant 
virus suggested the possibility of the emergence of 
a revertant virus with increased fitness. To test this 
hypothesis, we took clarified supernatants from the day 
25 cultures for both viruses and used them to begin new 
infections in fresh JLTRG cells. We observed that the 
passaged ROD10(14 Env) stock was now able to repli-
cate with similar kinetics as the ROD10(WT Env) virus 
(Fig.  5b), suggesting that changes had occurred that 
Fig. 3 An alanine face on tetherin is required for sensitivity to HIV-2 Env. a HIV-1 VLPs were produced in the presence of wild-type tetherin, or 
mutant tetherins with single amino acid changes at position 100, together with ROD10 Env or HIV-1 Vpu. VLP release was analyzed by Western blot-
ting and results normalized to the no tetherin control for n = 3 independent experiments, p < 0.05 (*). b The ability of ROD10 Env to bind tetherin 
mutant A100D was investigated by co-IP in 293T cells, using a GFP-tagged ROD10 Env. c The tetherin sequence from amino acids 95 through 108 
is shown above the solved 3D structure of a dimer of the protein’s extracellular domain [17], created using PyMOL software (Schrödinger LLC). Four 
conserved alanine residues are boxed, and highlighted in black on one monomer in the 3D structure. d Each of the four conserved alanines were 
individually mutated to aspartic acid, and the ability of the resulting tetherin mutants to restrict VLP release, and be counteracted by Vpu or ROD10 
Env, was assessed as previously described. Results were normalized to the no tetherin control, for n = 4 independent experiments, p < 0.05 (*).
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increased the replicative fitness of this mutant virus, 
either by restoring anti-tetherin activity or through an 
alternate compensatory mechanism such as enhanced 
cell-to-cell spread.
Revertant ROD14 Env mutants have acquired the ability 
to counteract tetherin
To examine the possibility that the wildtype kinetics 
of the passaged ROD10(14 Env) virus was due to the 
Fig. 4 Substitution of an alanine face in art-tetherin. a Schematic representation of tetherin, artificial tetherin (art-tetherin), and art-tetherin deriva-
tives with insertions of the alanine face (amino acids 95–108), at position 114–117 of art-tetherin. b HIV-1 VLPs were produced in 293A cells as previ-
ously described in the presence of ROD10 Env or the control Ebola GP (EboGP) expression plasmids. Additionally, art-tetherin (500 ng), insert 114, or 
insert 116 (1 μg each) were included and VLP release was analyzed as previously described, with results normalized to the no tetherin control, for 
n = 3 independent experiments, p < 0.05 (*). c 293T cells were co-transfected with the indicated artificial-tetherin variants and GFP-tagged ROD10 
Env. Cells were lysed 24 h later and GFP-tagged proteins immunoprecipitated (IP) with anti-GFP MicroBeads, followed by Western blotting of the 
input lysates (1%) and IP products using anti-Env, anti-GFP, anti-HA (for art-tetherin) or anti-tetherin antibodies.
Fig. 5 Replication of ROD10 and ROD14 Env viruses. a Viruses containing either the wild-type ROD10 Env [ROD10(WT Env)] or the mutant ROD14 
Env protein that does not counteract tetherin [ROD10(14 Env)] were produced in 293T cells and 3 μg p27 equivalent of supernatants were used to 
infect 5 × 106 JLTRG cells. A fraction of the cells were analyzed by flow cytometry at day 4, then every 3 days, for GFP expression. b Virus from day 
25 in the initial infections was transferred to fresh JLTRG cells and the cells monitored by flow cytometry. Infections were stopped at day 12, when it 
was observed that all viruses were replicating with wild-type kinetics.
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acquisition of an anti-tetherin activity, we isolated DNA 
from the second round of infections and sequenced the 
Env genes. For the ROD10(14 Env) stock, analysis of 9 
different Env clones revealed that they all retained the 
signature ROD14 Env mutations previously reported to 
account for the protein’s loss of ability to counteract teth-
erin (i.e. R422 and T598). Interestingly, however, the Envs 
had also acquired several new mutations at other sites 
that differed from the parental sequence. The pattern of 
these mutations appeared to suggest a serial acquisition 
of mutations, and were designated Rev A–C (Fig. 6a).
To determine whether these mutations had produced 
Env proteins with anti-tetherin activity, we performed 
VLP release assays using expression plasmids for each 
of the Rev A–C Envs (Fig.  6b). We found that the first 
mutant in the series, Rev A, was not able to counteract 
tetherin. However each of the remaining proteins had 
acquired some activity, albeit to a lesser extent than the 
wild-type ROD10 Env. The ability of the mutations in Rev 
B to restore this activity demonstrates that mutations in 
the ectodomain of the ROD14 Env that prevent anti-teth-
erin activity can be compensated for by alterations in the 
cytoplasmic tail alone.
We next assessed if the anti-tetherin phenotype of 
this series of Envs matched their ability to interact with 
tetherin in a co-immunoprecipitation assay. Mirroring 
the virus release assay results, we found that the Rev A 
Env did not immunoprecipitate tetherin any more than 
the background levels observed with the non-functional 
ROD14 parent, while the Rev B, C1, and C2 Envs had 
all re-acquired some ability to interact with tetherin 
(Fig.  6c). These findings further support the idea that a 
direct physical interaction with tetherin is required for 
antagonism by HIV-2 Env and, additionally, that tetherin 
imposes an evolutionary pressure on HIV-2 to evolve 
such a tetherin counteraction strategy.
Finally, we evaluated which of the three common cyto-
plasmic tail mutations present in functional Rev B, C1 
and C2 variants were necessary for this phenotype by 
evaluating single and double combinations. The lack of 
activity of mutant Rev A had implicated D830G as essen-
tial, but this further analysis revealed that both of the 
substitutions D830G and K796R were required (Fig. 6c).
Rev B Env cytoplasmic tail changes are not sufficient 
to confer anti‑tetherin activity
We further investigated the changes that had occurred 
in the cytoplasmic tail of the Rev B Env by examining 
whether this tail alone was now capable of conferring an 
anti-tetherin function. Such a situation would be simi-
lar to a previous report in which a Nef-deleted SIV virus 
acquired mutations within the cytoplasmic tail of its Env 
protein, which introduced a capability to interact with, 
and antagonize, tetherin [44]. To examine this possibil-
ity, we created chimeric proteins containing the extracel-
lular and transmembrane domains of HIV-1 Env, which 
has no anti-tetherin activity, linked to the cytoplasmic 
tails of either ROD10 Env (E1C10) (Fig. 7a), ROD14 Env 
(E1C14), or revertants A and B (E1CRev A, E1CRev B). 
We have previously shown that similar to the HIV-1 Env 
parent, the E1C10 chimera does not counteract tetherin 
[35]. To facilitate analysis by Western blotting, C-ter-
minal FLAG tags were included on all proteins, includ-
ing the parental ROD10 and ROD14 Envs. The resulting 
Env proteins were assayed for their ability to stimulate 
HIV-1 VLP release in the presence of tetherin (Fig. 7b). 
However, none of the proteins demonstrated evidence of 
anti-tetherin activity, indicating that the cytoplasmic tail 
domain of the Rev B Env was not sufficient to counteract 
tetherin when presented in this heterologous context.
Discussion
The cell surface protein BST-2/tetherin exhibits several 
antiviral activities that derive from its ability to retain 
newly assembled virions at the surface [8–10]. Such 
tethered viruses result in a reduction in the production 
of cell-free virus, enhance presentation to the immune 
system [11–13], and lead to the induction of an antivi-
ral state [14, 15]. To combat these activities, a range of 
approaches have evolved in the primate lentiviruses 
through adaptations in the Vpu, Nef or Env proteins of 
specific viruses. These antagonists act to reduce the 
amount of tetherin at the cell surface following intracellu-
lar sequestration [27–29, 37], displacement from the sites 
of viral budding [34, 45], and/or enhanced degradation 
[30–32]. These mechanisms appear to all involve direct 
or possibly indirect interactions between tetherin and the 
viral antagonists, since tetherin can be immunoprecipi-
tated by each viral protein. To do this, multiple domains 
in tetherin are targeted, including the cytoplasmic tail by 
SIV Nef [26], the transmembrane region by HIV-1 Vpu 
[30, 46–48] and the extracellular domain by HIV-2 Env.
We confirmed a physical interaction between tetherin 
and HIV-2 Env by co-immunoprecipitation, and further 
determined that previously identified mutations in the 
ROD14 Env that abolished anti-tetherin activity also pre-
vented this interaction. Furthermore, we identified an 
alanine face on the extracellular helical domain of teth-
erin as being necessary for the interaction, with substitu-
tions at any one of four alanine residues both preventing 
co-immunoprecipitation and rendering human tetherin 
resistant to the HIV-2 Env. However inserting the alanine 
motif into an artificial tetherin-like molecule was not suf-
ficient to convert the molecule to a form that could co-
immunoprecipitate with the HIV-2 Env, or that was now 
sensitive to its antagonism, suggesting that the alanine 
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motif is necessary, but not sufficient, for the tetherin-Env 
interaction.
Interestingly, an alanine face has also been implicated 
in the interaction between Vpu and tetherin [33, 47–49], 
occurring in the trans-membrane region of Vpu. Alanine 
faces have also been implicated in other protein–pro-
tein interactions, promoting homodimerization in other 
transmembrane domains [50, 51] and in receptor-agonist 
interactions [52, 53]. Although it was originally specu-
lated that the alanine face in Vpu represented a direct 
Fig. 6 ROD14 Env reacquires anti-tetherin activity when passaged in culture. a Schematic of sequences in 9 independent clones isolated from 
ROD10(14 Env) infected JLTRG cells, with mutations shown relative to where they occur in either the gp120 or gp41 subunits. The mutations 
designated Rev A were found in all 9 clones, Rev B was in 7 out of 9 clones, and Rev C1 and C2 both occurred in 2 out of 9 clones each. All 9 clones 
retained the original ROD14 Env mutations R422 and T598, associated with loss of anti-tetherin activity. MSD is membrane-spanning domain. b 
The indicated Env clones were tested at two separate amounts, 2 and 4 μg (×2), in a VLP release assay in 293A cells in the presence of tetherin, as 
previously described. Results were normalized to the no tetherin control, for n = 3 independent experiments, p < 0.05 (*). c Revertant Envs were 
GFP-tagged and tested for their ability to co-IP with tetherin in 293T cells, as previously described. d Indicated Env clones, including single and dou-
ble substitutions in the ROD14 Env backbone, were tested in a VLP release assay in 293A cells in the presence of tetherin. Results were normalized 
to the no tetherin control, for n = 3 independent experiments, p < 0.05 (*).
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tetherin interaction face, cysteine-scanning mutagen-
esis and crosslinking experiments have instead pointed 
to a role for the motif in maintaining the overall struc-
ture of Vpu in a form that is competent to target tetherin 
[34]. Therefore, while we cannot rule out that the lack 
of HIV-2 Env recognition of the art-tetherin molecules 
substituted with the alanine motif was caused by a less 
than optimal presentation in the context of this chimeric 
construct, it is also possible that the motif is not a direct 
interaction face, and is instead involved in maintaining 
the overall structure and organization of the protein’s 
ectodomain.
Although all of the major groups of the primate len-
tiviruses express anti-tetherin factors [8, 9, 21–23, 37], 
and their activity is easy to observe in one-round virus 
release assays, the importance of these activities has been 
less consistent in studies of virus replication. For exam-
ple, studies of wild-type and Vpu-deficient HIV-1 have 
reported either less efficient replication for the mutant 
viruses [54–56], or no effect [57]. Using a similar in vitro 
replication assay for HIV-2 expressing the ROD10 or 
ROD14 Envs, we were able to observe a distinct dif-
ference in replication rates. Furthermore, the ROD14 
mutant acquired wild-type replication kinetics after pas-
sage in culture, consistent with a strong selection pres-
sure to restore, or compensate for, the loss of this activity.
Analysis of the passaged viruses revealed that they 
had not undergone a simple reversion back to the WT 
(ROD10) Env sequence. Instead, we observed both 
retention of the original deleterious mutations (K422R 
and A598T) and the acquisition of additional mutations 
throughout the protein. Interestingly, we found that the 
minimal changes required to restore anti-tetherin activ-
ity mapped to the cytoplasmic domain of the protein, 
specifically K796R, and D830G. Further analysis revealed 
that substitutions in the cytoplasmic tail also restored 
the ability to interact with tetherin in a co-immunopre-
cipitation assay, despite the presence of the ROD14 ecto-
domain mutations, and further suggesting that direct 
interactions between the two proteins is an essential part 
of tetherin antagonism by the HIV-2 Env.
We have previously mapped the anti-tetherin func-
tion of the HIV-2 Env to the ectodomain of the protein 
[35]. These findings of compensatory changes in the 
cytoplasmic tail suggested that either the mutations had 
created an additional tetherin-interacting domain in this 
region, or that the changes in the tail were having long-
range effects on the conformation of the ectodomain and 
thereby restoring activity. Support for the former hypoth-
esis comes from the characterization of Nef-deleted SIV 
variants that were used to infect macaques and which 
eventually acquired a new tetherin-binding domain in 
the cytoplasmic tail of Env [44]. However, chimeras cre-
ated between the HIV-1 Env and these mutant cytoplas-
mic domains were unable to block tetherin restriction, 
ruling out this potential explanation. Instead, we favor 
a model where these mutations in the cytoplasmic tail 
have an ‘inside-out’ influence on the conformation of 
the ectodomian, and allow more permissive interac-
tions. Long-range impacts of a cytoplasmic domain on 
Fig. 7 Analysis of ROD14 Env cytoplasmic tail revertants. a Schematic representation of the Env proteins from HIV-1 (isolate BH10), ROD10, and 
the chimeric protein E1C10, containing the extracellular and transmembrane domains of BH10 and the cytoplasmic domain of ROD10 Env. Similar 
chimeras were produced containing the BH10 extracellular domain and the cytoplasmic (C) domain of RO10, RODD14, Rev A and Rev B. MSD is 
membrane-spanning domain. The ability of each Env to counteract tetherin restriction is also noted [35]. b HIV-1 VLPs were produced in 293A cells 
in the presence of tetherin (100 ng), alone or together with each Env (2 μg). The percent VLP release was determined as described previously with 
results normalized to the no tetherin control, for n = 4 independent experiments, p < 0.05 (*).
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the structure and function of a protein’s ectodomain have 
previously been described [58–62]. Finally, it is also pos-
sible that these cytoplasmic tail mutations could be hav-
ing a more indirect effect by altering the sub-cellular 
localization or cell surface stability of the HIV2 Env, and 
thereby enhancing the activity of a less potent tetherin 
antagonist.
Conclusions
BST-2/tetherin inhibits the release of budding lenti-
viruses. To prevent this action, HIV-2 Env sequesters 
tetherin in an intracellular location, in a mechanism that 
requires an interaction between the two proteins and 
which involves their ectodomains. We have mapped an 
alanine face in tetherin that is required, and shown that 
residues in both the ectodomain and cytoplasmic tail of 
Env can influence this interaction. HIV-2 viruses with at 
least one class of mutant Env protein (ROD14) reacquire 
this ability when passaged in culture due to second site 
mutations in the cytoplasmic tail, illustrating the impor-
tance of this anti-tetherin activity for viral fitness.
Methods
Cell lines
293T cells were obtained from the American Type Cul-
ture Collection; 293A cells were obtained from Qbio-
gene/MP Biomedicals (Irvine, CA, USA) and JLTRG cells 
[63] were obtained from the AIDS Research, Reference, 
and Reagent Program (ARRRP). 293A and 293T cells 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Mediatech, Herndon, VA, USA) supplemented 
with 10% fetal bovine serum (FBS) (Denville, Metuchen, 
NJ, USA) and JLTRG cells maintained in RPMI-1640 
(Mediatech) supplemented with 10% FBS and 1% penicil-
lin/streptomycin (JR Scientific, Woodland, CA, USA).
Plasmids
Plasmid pHIV-1-pack expresses HIV-1 Gag-Pol and Rev 
and produces HIV-1 virus-like particles (VLPs) [35]. 
Plasmid pcDNA-Vphu (Vpu) encodes a human codon-
optimized form of Vpu from HIV-1 isolate NL4-3 [64]. 
Plasmid pEboGP expresses Ebola Zaire GP-8A, the full-
length form of the Ebola virus glycoprotein [38]. The 
HIV-2 Env expression plasmids pROD10 Env, pROD14 
Env, and pROD10Y707A Env have previously been 
described [35, 39]. C-terminal eGFP tagged versions of all 
Env clones were generated by 2-step PCR using plasmid 
pAcEGFP-N1 (Clonetech, Moutainview, CA, USA) as an 
eGFP template. A GPI anchored version of the extracel-
lular domain of ROD10 Env was created by 2-step PCR 
to fuse residue Trp673 of Env to the GPI domain (codons 
303–335) from the urokinase-type plasminogen activator 
receptor (uPAR) [65]. Expression plasmids for tetherin/
BST-2, an eGFP-tagged tetherin/BST-2, and an artificial 
tetherin (art-tetherin) have been previously described 
[20, 29, 38]. Art-tetherin mutants containing insertions 
of tetherin residues 96–108 were generated by 2-step 
PCR. The infectious ROD10 proviral clone [36, 66] was 
kindly provided by Klaus Strebel (NIH). Derivatives were 
created containing either the ROD14 or the ROD10Y707A 
Envs in the ROD10 backbone, using restriction sites 
BstAPI and BsmI at positions 8582 and 9437 in the 
genome. Chimeric proteins containing the transmem-
brane and extracellular domains of HIV-1 Env and the 
cytoplasmic domain of HIV-2 Env were created by 2-step 
PCR using the HIV-1BH10 proviral clone and the HIV-
2ROD10 expression plasmids as templates, as previously 
described [35], and using a reverse primer that added a 
FLAG tag at the carboxyl terminus of the Env protein.
Production and analysis of HIV‑1 VLPs
HIV-1 VLPs were generated from 293A cells by transient 
transfection of pHIV-1-pack using TurboFect transfec-
tion reagent (Thermo Scientific, Glen Burnie, MD, USA), 
as previously described [24]. The following amounts of 
plasmid DNA were used per 10-cm plate of cells: 2 μg of 
Vpu, Ebola GP and all HIV-2 Env constructs; 100 ng of 
tetherin and derivatives; 500  ng of art-tetherin; 1 μg of 
art-tetherin mutants. Cell lysates and viral particles were 
collected at 24 h post-transfection and the levels of p24 
proteins in both lysates and supernatants analyzed by 
Western blot, as previously described [29, 35, 38, 39]. 
The intensity of p24-reacting bands on Western blots 
was measured and calculated as the ratio of the signal 
in VLPs:lysates, normalized to the ratio for the pHIV-
1-pack only control. Specific proteins were detected by 
Western blotting using the following antibodies: rabbit 
ant-HIV-1SF2 p24 at 1:3,000 dilution, rabbit anti-HIV-2ST 
SU at 1:3,000 dilution, rabbit anti-tetherin at 1:10,000 
dilution, and rabbit anti-HIV-1 Vpu at 1:3,000 dilution 
(all from ARRRP), as well as rabbit anti-GFP at 1:3,000 
dilution (Abcam, Cambridge, MA, USA) and mouse anti-
FLAG at 1:1,000 (Roche Applied Science, Indianapolis, 
IN, USA). The secondary antibodies used were HRP-
conjugated goat anti-rabbit IgG at a 1:10,000 (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) and goat anti-
mouse IgG (1:10,000) (Sigma-Aldrich, St. Louis, MO, 
USA). Statistical analysis was performed using one-way 
ANOVA followed by Dunnett’s multiple comparison test 
from GraphPad Prism 5.0 (GraphPad Software, La Jolla, 
CA, USA).
Co‑immunoprecipitation
293T cells in 10-cm dishes were co-transfected by Tur-
boFect using 200 ng of tetherin plasmid and 2 μg of the 
indicated eGFP-tagged HIV-2 Env plasmids or 200  ng 
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of eGFP-tagged tetherin and either 2  μg of untagged 
ROD10 Env or the indicated amount of ROD10 Envgpi. 
Cell lysates were collected at 24 h post transfection and 
GFP pull-down assays performed using the μMACS GFP 
isolation kit (Miltenyi Biotech Inc., Auburn, CA, USA). 
Initial cell lysates (1% input) and immunoprecipitates 
were analyzed by Western blotting.
Flow cytometry for Env surface expression
293A cells were in 10-cm dishes were co-transfected by 
Turbofect with 100 ng of an eGFP expression vector and 
either 2 μg of ROD10 Env or 2–8 μg amounts of ROD10 
Envgpi. Twenty-four hours later, cells were washed 3× 
with PBS then blocked in 10% FBS for 30 min. Cells were 
then stained with HIV-2ST Su antibody 1410 at a 1:300 
dilution for 15  min at 4C. Cells were washed 3× with 
PBS then counterstained with goat anti-rabbit IgG con-
jugated to Alexa Fluor 647 (Invitrogen) at a 1:300 dilution 
for 20 min for an additional 15 min. GFP + cells (10,000 
events) were analyzed on a BD FACS Canto II (BD Bio-
sciences, San Jose, CA, USA)., and collected data was 
analyzed using FlowJo 6.2 software (Tree Star, Ashland, 
OR, USA). The mean fluorescence intensity (MFI) was 
determined within the software and compared to cells 
stained with secondary antibody alone.
Viruses and infections
HIV-2 stocks were produced in 293T cells by transient 
transfection using TurboFect and 10 μg of proviral plas-
mids, followed by harvesting and filtration of superna-
tants 48  h later. Stocks were quantitated using a HIV-2 
p27 ELISA kit (Zeptometrix, Buffalo, NY, USA). Infec-
tions were performed by incubating 5 × 106 JLTRG cells 
with the equivalent of 3  μg of p27 in a total of 0.5  ml 
RPMI for 4 h, followed by replacement of the media with 
5  ml fresh media. Every 3  days, cells were analyzed for 
GFP expression by flow cytometry using a FACS Canto 
II, with uninfected cells used to set the negative popula-
tion. At each data point, 20,000 cells were collected and 
the data analyzed using FlowJo 6.2 software. 0.45 μm fil-
ter clarified supernatants from infected JLTRG cultures 
were equilibrated and added to fresh JLTRG cells for 4 h 
to initiate second round infections that were then tracked 
by flow cytometry analysis every 3 days.
Viral sequences from infected cells were obtained by 
isolating genomic DNA (Qiagen, Valencia, CA, USA), 
followed by PCR amplification using the Accuprime 
Taq DNA Polymerase system (Invitrogen, Carlsbad, 




added a FLAG tag to the cytoplasmic tail. PCR products 
were ligated into a TOPO-TA cloning vector (Invitrogen) 
and single clones selected and sequenced.
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